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ABSTRACT
Introduction: Psychosocial and rehabilitation
interventions are increasingly used to attenuate
disability and improve health-related quality of life
(HRQL) in chronic diseases, but are typically not
available for patients with rare diseases. Conducting
rigorous, adequately powered trials of these
interventions for patients with rare diseases is difficult.
The Scleroderma Patient-centered Intervention Network
(SPIN) is an international collaboration of patient
organisations, clinicians and researchers. The aim of
SPIN is to develop a research infrastructure to test
accessible, low-cost self-guided online interventions to
reduce disability and improve HRQL for people living
with the rare disease systemic sclerosis (SSc or
scleroderma). Once tested, effective interventions will
be made accessible through patient organisations
partnering with SPIN.
Methods and analysis: SPIN will employ the cohort
multiple randomised controlled trial (cmRCT) design,
in which patients consent to participate in a cohort for
ongoing data collection. The aim is to recruit 1500–
2000 patients from centres across the world within a
period of 5 years (2013–2018). Eligible participants are
persons ≥18 years of age with a diagnosis of SSc. In
addition to baseline medical data, participants will
complete patient-reported outcome measures every
3 months. Upon enrolment in the cohort, patients will
consent to be contacted in the future to participate in
intervention research and to allow their data to be used
for comparison purposes for interventions tested with
other cohort participants. Once interventions are
developed, patients from the cohort will be randomly
selected and offered interventions as part of pragmatic
RCTs. Outcomes from patients offered interventions
will be compared with outcomes from trial-eligible
patients who are not offered the interventions.
Ethics and dissemination: The use of the cmRCT
design, the development of self-guided online
ARTICLE SUMMARY
Article focus
▪ Psychosocial and rehabilitation interventions are
used to attenuate disability and improve
health-related quality of life (HRQL) in many
chronic diseases, but are typically not available
for people with rare diseases.
▪ Conducting rigorous, adequately powered trials
of these interventions for patients with rare dis-
eases is difficult.
▪ The Scleroderma Patient-centered Intervention
Network (SPIN) is an international collaboration
of patient organisations, clinicians and research-
ers whose aim is to develop a research infra-
structure to test accessible, low-cost, self-guided
online interventions to reduce disability and
improve HRQL for people living with scleroderma
(systemic sclerosis).
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interventions and partnerships with patient organisations will allow
SPIN to develop, rigourously test and effectively disseminate
psychosocial and rehabilitation interventions for people with SSc.
INTRODUCTION
Providing better patient-centred care for people living
with chronic diseases is increasingly prioritised in propo-
sals to improve healthcare.1 Patient-centred care empha-
sises patient empowerment through shared
decision-making, the development of care plans that
take into consideration patient preferences and values,
and the tailoring of care to meet the speciﬁc needs of
individual patients.2–4 Comprehensive care to attenuate
disability and improve health-related quality of life
(HRQL) in chronic diseases involves a combination of
both pharmacological and non-pharmacological inter-
ventions.5 People with rare diseases do not, however, typ-
ically have access to disease-speciﬁc psychosocial and
rehabilitation interventions that are important compo-
nents of patient-centred care.
The lack of accessible, evidence-based, disease-speciﬁc
interventions is an important gap in patient care. Many
people with rare diseases face unique challenges that are
not addressed by generic interventions or interventions
developed for other chronic diseases.6 However, there
are major obstacles to developing, evaluating and deli-
vering psychosocial and rehabilitation interventions to
meet the speciﬁc needs of people with rare diseases. An
important barrier is the small number of people with a
given rare disease at any single centre. Furthermore,
most clinical research centres are often involved in many
different trials and tend to prioritise trials of primary
disease treatment over non-pharmacological interven-
tion trials to reduce disability and improve HRQL.
Illustrating the extent of this problem, we conducted a
PubMed search (‘randomized controlled trial’ (publication
type) NOT ‘drug therapy’ (subheading)) of the 6632 rare
diseases listed by the US National Institutes of Health7
and found only one randomised controlled trial (RCT)
of a psychosocial or rehabilitation intervention with the
sample size of at least 100 patients,8 a relatively small
number given typical sample size requirements to evalu-
ate most psychosocial and rehabilitation interventions.9 10
Thus, for most rare diseases, there are either no trials
that have tested psychosocial and rehabilitation interven-
tions or only very small trials that are useful to evaluate
feasibility, but inadequate for assessment of treatment
efﬁcacy.11–13
Beyond difﬁculties conducting RCTs, many factors
also complicate the delivery of psychosocial and rehabili-
tation interventions to people with rare diseases. Few
centres treat enough patients with a given rare disease to
sustain a disease-speciﬁc psychosocial and rehabilitation
intervention programme. Additionally, many patients
with rare diseases live far from major treatment centres.
These individuals often receive care in local settings
from healthcare providers with little or no experience
treating their disease and without knowledge about the
speciﬁc needs of people with the disease. Patients who
live in rural areas far from specialised care are often left
to cope with their illness essentially alone, may lack even
relatively basic information about their disease, and, in
many cases, experience substantial difﬁculty coping.14 15
Thus, ﬁnding a way to develop, test and deliver psycho-
social and rehabilitation interventions for patients with
rare diseases in a cost-effective manner is an important,
but unsolved problem.
Systemic sclerosis (SSc, also known as scleroderma) is
a rare disease where patients have important unad-
dressed psychosocial and rehabilitation needs.16 17 SSc is
an autoimmune connective tissue disease characterised
by vascular injury, immune dysfunction and an abnormal
ﬁbrotic process that can affect multiple organ systems
including the skin, lungs, gastrointestinal tract and car-
diovascular system.18 19 Conditions commonly associated
with SSc include Raynaud’s phenomenon,20 oesophageal
disease and chronic gastrointestinal symptoms (dyspha-
gia, dyspepsia, diarrhoea, chronic constipation and mal-
absorption),21 and pulmonary disease (interstitial lung
disease, pulmonary vascular disease, pulmonary arterial
hypertension).18 19 Prevalence estimates for SSc range
from 7 to 489 cases per million, and approximately 80%
of patients diagnosed with SSc are women.22 23
SSc is notable for a wide range of patient-reported
problems, including limitations in physical mobility and
hand function, pain, fatigue, sleep disturbance, depres-
sion, sexual dysfunction and body image distress from
disﬁguring changes in appearance (eg, pigment
ARTICLE SUMMARY
Key messages
▪ SPIN will employ the cohort multiple randomised controlled
trial (cmRCT) design, in which patients consent to participate
in a cohort for ongoing data collection.
▪ The cohort framework will also be used to identify patients eli-
gible for internet-based psychosocial and rehabilitation inter-
ventions that will be developed by SPIN investigators and to
conduct feasibility and, subsequently, full-scale trials of these
interventions.
▪ Once tested, effective interventions will be made accessible
through patient organisations partnering with SPIN.
Strengths and limitations of this study
▪ In the context of rare diseases, the advantage of the cmRCT
design to conduct multiple trials that draw participants from
the same patient cohort is particularly important given the diffi-
culty of recruiting a sufficiently large patient group for any
single trial.
▪ Unique features of SPIN, including the use of the cmRCT
design, the development of self-guided online interventions
delivered using a common platform, and a robust partnership
with patient organisations, may serve as a model to help facili-
tate research in this area for other rare diseases as well.
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changes, hand contractures and facial telangiecta-
sias).16 24–27 There are no disease-modifying treatments
for SSc and its management is predicated on identifying
organ-speciﬁc disease manifestations and initiating
targeted therapies (eg, calcium channel blockers
for Raynaud’s phenomenon, proton-pump inhibitors
for gastrointestinal reﬂux disease and ACE inhibitors for
SSc renal crisis).17 Because there is no cure, a primary
goal of care is to reduce symptoms and disability, and to
improve HRQL. However, as with many rare diseases,
evidence-based psychosocial and rehabilitation interven-
tions to meet the speciﬁc needs of patients with SSc are
not available. The authors of recent guidelines for SSc
management17 noted the potential importance of psy-
chosocial and rehabilitation interventions in disease
management, but could not make recommendations for
or against these types of interventions due to a general
lack of evidence.
The Scleroderma Patient-centered Intervention
Network (SPIN),28 an international collaboration of
patient organisations, clinicians and researchers was
recently organised and funded by the Canadian Institutes
of Health Research to address this important gap. The
long-term goals of SPIN are to develop, test and dissemin-
ate accessible interventions to complement standard
medical care and improve HRQL outcomes in SSc. Once
tested, effective interventions will be made accessible to
patients with SSc through patient organisations around
the world. SPIN currently is developing a series of inter-
ventions, including (1) general SSc self-management, (2)
support for better coping with emotional distress; (3)
support for managing body image distress and (4) phys-
ical and occupational therapy for hands. Other interven-
tions that address areas important to people with
scleroderma (eg, fatigue and energy management, sleep
problems and sexual function) may be developed subse-
quently, depending on need and funding availability.
An important characteristic of SPIN is that all inter-
ventions will be delivered in a self-guided online format.
Across medical ﬁelds, online delivery of interventions is
increasingly common, and these interventions have suc-
cessfully improved HRQL.29–31 The utilisation of web-
based technology is particularly important in the case of
rare diseases where patients typically have difﬁculty
accessing specialised services. A recent study32 found
that 85% of Dutch patients with SSc had used the inter-
net to search for information about SSc and that most
of these patients (77–88%) perceived access to online
information on physical, psychological and social conse-
quences of the disease as important.
SPIN will utilise a novel research design, the cohort
multiple RCT (cmRCT) design,33 to collect longitudinal
data related to problems experienced by people living
with SSc and as a framework for developing, evaluating
and delivering psychosocial and rehabilitation interven-
tions. The aim of this article is to illustrate the use of the
cmRCT design in a rare-disease context, which may
serve as a model to help facilitate research in the area of
non-pharmacological interventions for other rare dis-
eases as well.
SPIN COHORT AIMS
The ﬁrst step towards SPIN’s long-term goals is the estab-
lishment of the SPIN Cohort. The speciﬁc aims of the
SPIN Cohort are to:
1. Collect observational data at regular intervals on an
ongoing basis in order to conduct research on pro-
blems identiﬁed by patients with SSc as important to
them and to determine the best way to measure out-
comes related to these problems, among other
research questions that may be addressed via the
cohort;
2. Use the cohort framework to identify patients eligible
for internet-based psychosocial and rehabilitation
interventions that will be developed by SPIN investi-
gators and to conduct feasibility and, subsequently,
full-scale trials of these interventions.
METHODS AND ANALYSIS
Design
The cmRCT design,33 which SPIN will employ, was devel-
oped to take advantage of the beneﬁts of cohort designs
for longitudinal data collection and to address some
important limitations to traditional RCT designs in the
context of pragmatic RCTs. Pragmatic RCTs are
intended to test the effectiveness of an intervention in
everyday practice with relatively unselected participants
and under ﬂexible conditions, maximising the applic-
ability of the trial’s results to usual care settings.34 They
differ from explanatory trials in that pragmatic trials are
meant to inform decisions about practice rather than
explain mechanistic aspects of an intervention under
ideal circumstances. In this respect, pragmatic trials are
well suited to assess whether patients beneﬁt from
adding an intervention to treatment as usual, compared
with treatment as usual only.
The cmRCT design involves recruitment of an obser-
vational cohort, in which patients ﬁll out a small set of
core outcomes regularly. Patients enrolled in the cohort
agree to allow their longitudinal data to be used in the
aggregate. They also allow their data to be used to iden-
tify them to be invited to participate in research inter-
ventions, once developed, or for comparison purposes
for intervention trials that may be conducted with other
patients while they are participating in the cohort. In
the cmRCT design, as described to patients when they
consent to participate in the cohort, only eligible
patients randomly selected to be offered an interven-
tion, but not eligible non-selected patients, are con-
tacted and offered treatment. Eligible patients not
selected are not notiﬁed about the trial. Consent for spe-
ciﬁc trials will be obtained from those eligible patients
who are invited and accept the offer to participate.
Postintervention outcomes among eligible patients who
accept the offer to receive the intervention will be
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compared with outcomes among patients from the
cohort who were identiﬁed as eligible for the interven-
tion, but were not offered the intervention and not con-
tacted about the intervention.
In the context of rare diseases, the advantage of the
cmRCT design to conduct multiple trials that draw parti-
cipants from the same patient cohort is particularly
important given the difﬁculty of recruiting a sufﬁciently
large patient group for any single trial. No single trial
will adequately address the psychosocial and rehabilita-
tion needs of patients with a rare disease, such as SSc.
The cmRCT design will enable the implementation of
multiple trials over time with different inclusion and
exclusion criteria, which, together, have much greater
potential in this regard.
In many areas of research, interventions are tested in
isolation, typically including different patient groups by
different research teams. The cmRCT design allows for
tests of interventions that can be compared in the same
overall population with similar trial methods, thus
increasing the ability to compare and contrast different
trial results. Furthermore, whereas the ability to collect
long-term outcomes is often limited in single RCTs, core
patient measures are assessed on an ongoing basis in the
cmRCT model. Thus, key outcomes can be obtained
over a long period post-trial for patients who participate
in trials.
The cmRCT design also offers advantages in that the
patient consent process more closely replicates what
occurs in actual healthcare settings compared with the
consent procedures typically used in traditional RCT
designs. In traditional RCTs, patients are usually told
that they will be randomised to obtain the trial interven-
tion or an alternative, which in pragmatic trials of psy-
chosocial and rehabilitation interventions is generally
usual care. In real-life healthcare situations, patients are
only told of treatments that their healthcare provider
can provide with certainty, and they are not told that the
treatment they receive will be decided by chance. In the
cmRCT design, patients are told about treatments that
they will be able to access if they so choose.33 As part of
the initial consent process, patients are made aware that
a number of trials may occur via the cohort, and that
they will not likely be offered to participate in all of
them and may not be offered to participate in any. It is
explained that patients will only be notiﬁed about trials
for which they will be offered the intervention, but that
their data may be used for comparison purposes in the
context of some interventions not offered to them.
Beyond increasing the ecological validity of the
recruitment and consent process itself, it is possible that
the cmRCT approach may increase the representative-
ness of trial participants, and thus the generalisability of
results. Indeed, concerns about information and
consent are the most common reasons for patients not
participating at all in traditional RCTs.35 These concerns
likely play a role in the relatively low trial participation
rates and may reduce the ecological validity of trials if
patients who consent to participate comprise a small
and qualitatively different group than the overall patient
population who will receive the intervention in practice.
Because the cmRCT design collects data on patients
before they have accepted or refused the intervention,
the cmRCT design also allows for collection of import-
ant information about the reasons that patients refuse
an intervention and why certain patients were unable to
complete the assigned intervention. This information is
valuable both for assessing the validity of modelling
assumptions and for predicting the success of the inter-
vention in the general population.
In many pragmatic trials of psychosocial and rehabili-
tation interventions patients who consent to participate
in a trial may do so because they would like the oppor-
tunity to receive the trial intervention rather than treat-
ment as usual. Patients cannot usually be fully blinded
regarding whether treatment has been offered.
Therefore, patients randomised into the ‘treatment as
usual’ arm, may be disappointed and some may even
withdraw from the study, leading to attrition bias that
might inﬂuence the results of the trial. This disappoint-
ment can also inﬂuence the perception of care and
reporting of trial outcomes for patients who do not with-
draw, but who are aware that they did not receive the
treatment.36 In the cmRCT design, patients will be
aware when they do receive an intervention, but not
when they have not been selected for an intervention
trial, thus, potentially reducing the possibility of disap-
pointment bias.
The use of the cmRCT design by SPIN to facilitate
research on non-pharmacological interventions for
people with SSc is feasible due to the international, multi-
centre nature of the network, which will facilitate the
inclusion of a sufﬁcient number of patients with SSc in
the SPIN Cohort. Initially, the SPIN Cohort will be used
to describe and better understand the nature of pro-
blems that have been identiﬁed by people with SSc as
important16 28 and to determine optimal outcome mea-
sures to use in SPIN intervention trials. Once SPIN inter-
ventions are developed, patients eligible for a given trial
will be identiﬁed based on trial-speciﬁc criteria using
core SPIN Cohort measures (see online supplementary
appendix 1), and a random selection of these eligible
patients will be offered the trial intervention (ﬁgure 1).
In the SPIN Cohort, patients can participate in one SPIN
intervention at the time, but may be offered to partici-
pate in more than one SPIN intervention sequentially.
Core outcomes (25–30 min to complete) will be assessed
every 6 months with brief 3-month assessments (5 min to
complete) in between. For patients who are eligible for a
SPIN intervention trial and are assigned to the interven-
tion or control groups, the 3-month assessment will also
include trial-speciﬁc measures. Since determination of
trial eligibility will be automated using routinely collected
cohort measures, all patients who are eligible for an
active SPIN trial at a given point in time will automatically
be administered the trial-speciﬁc measures.
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Study sample
We expect to initially recruit 1500–2000 patients for the
SPIN Cohort from SPIN centres in Canada, the USA,
France, the Netherlands, the United Kingdom, Spain,
Mexico and Australia over a period of 5 years (2013–
2018). Eligible participants will include patients ≥18 years
of age who have been identiﬁed by a SPIN physician as
having a diagnosis of SSc. Exclusion criteria for participa-
tion in the SPIN Cohort include having a medical disorder
that compromises the ability to give informed consent, not
having access to or not being able to respond to question-
naires via the internet, and not being able to respond to
questionnaires in an available SPIN language (currently
English, French, Spanish and Dutch).
Procedure
SSc patients treated by SPIN physicians will be recruited for
the SPIN Cohort at their site, and their written informed
consent will be obtained. The local participating SPIN
physician, or supervised nurse coordinator, will complete a
Medical Data form (see online supplementary appendix
2). This form will be submitted online to initiate patient
registration in the SPIN Cohort. After completion of regis-
tration by a recruiting SPIN physician, an automated wel-
coming email will be sent to participants with instructions
to complete the SPIN patient measures online. Two weeks
prior to each 3-month follow-up, participants will receive
an email reminding them to go online and complete their
forms. On the date of the follow-up assessment, a second
notiﬁcation email will be sent to patients, reminding them
to complete the questionnaires online. If 1 week after the
assessment date the questionnaire has not yet been
completed, an SPIN investigator will contact the patient to
encourage them to go online and complete the forms. If a
patient has not ﬁlled out the questionnaires within 2 weeks
after the assessment date, their data will not be collected
for that assessment cycle. Patients who do not complete
forms at a particular SPIN Cohort assessment are eligible
to continue in the SPIN Cohort and will be contacted for
subsequent assessments. If patients do not complete four
consecutive assessments, they will be considered to have
dropped out of the SPIN Cohort.
Measures
Medical information is obtained at baseline, and SPIN
Cohort participants will complete a core set of six mea-
sures online every 6 months. The core measures include
measures of overall health status and functional disabil-
ity, as well as measures of patient outcomes that will be
targeted by the initial set of SPIN interventions that are
under development (emotional distress, body image
concerns, hand function, disease self-management).
Additional measures will be integrated into the SPIN
Cohort periodically for the purpose of conducting
measurement-related substudies (with a total of 25–
30 min to complete). The core measures will determine
eligibility for SPIN feasibility trials and subsequent full-
scale trials, once initiated. At the 3-month interval
between two core measurement occasions, a brief assess-
ment of HRQL will be completed (5 min to complete).
For patients who are eligible for a SPIN intervention
trial (in both the intervention and control arms), this
3-month measurement will include trial-speciﬁc mea-
sures related to the trial outcomes of interest.
Figure 1 Outline of the cohort multiple randomised controlled trial design.
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Medical data
At the time of enrolment, recruiting SPIN physicians will
obtain and record basic demographic and medical data
from patients’ medical records. Medical information will
be recorded on a standardised form (see online supple-
mentary appendix 2) and will include height, weight,
date of onset Raynaud’s phenomenon and ﬁrst
non-Raynaud’s symptom, date of SSc diagnosis, disease
subtype, presence of autoantibodies, skin involvement,
presence of digital ulcers and pitting scars, joint involve-
ment, organ involvement and the presence of an
overlap syndrome.
Core measures
Overall health status will be assessed with the Patient
Reported Outcomes Measurement Information System-29
(PROMIS-29)37 and functional disability from SSc with the
Scleroderma Health Assessment Questionnaire (SHAQ).38
Depressive symptoms will be assessed with the Patient
Health Questionnaire-8 (PHQ-8).39–41 Body image con-
cerns due to changes in appearance from SSc will be
assessed with the Satisfaction with Appearance Scale
(SWAP).42–44 The Cochin Hand Function Scale45 will be
used to measure limitations in hand function. Self-efﬁcacy
for coping and disease self-management will be measured
using the Self-Efﬁcacy for Managing Chronic Disease
Scale.46 Further information on each measure is available
in online supplementary appendix 1.
Analysis plan
Sample size
We aim to recruit 1500–2000 patients for the SPIN
Cohort. This number will be sufﬁcient to conduct longi-
tudinal research on problems identiﬁed by patients with
SSc as important to them and to determine the best way
to measure outcomes related to these problems. We also
expect this to be a sufﬁcient number to identify and
recruit eligible patients to participate in future SPIN
trial studies, allowing us to conduct randomised con-
trolled trials with sufﬁcient statistical power. Sample size
calculations for SPIN trials will be determined for each
SPIN trial separately, and the appropriate sample size
calculations will be provided in all trial protocols.
SPIN Cohort
Initially, SPIN Cohort data will be used to gain a better
understanding of problems identiﬁed by patients as
important to them (eg, body image, physical limitations
and HRQL) via observational studies and to conduct
measurement studies to determine the best way to
measure outcomes related to these problems. All studies
that use data from the SPIN Cohort for these purposes
will be required to submit a proposal to the SPIN Data
Access and Publications Committee (see below). This
committee will ensure that all study designs are appro-
priate and that investigators adhere to a priori deﬁned
study and analysis plans.
Feasibility trials
Consistent with current best practice recommendations
for intervention development and testing,11–13 feasibility
trials for all SPIN interventions will be conducted via the
SPIN Cohort to ensure that trial methodology is sound,
feasible and consistent with patient expectations.11–13
Data will be collected to review the process (eg, feasibil-
ity of steps that need to take place in the full-scale
study), required resources (eg, time and budget), man-
agement issues (eg, related to optimising performance
of personnel and data systems) and scientiﬁc aspects
(eg, recruitment rates of eligible patients, acceptability
of intervention to patients and assessing performance of
outcome measures). For each intervention, semistruc-
tured interviews will be conducted with 15–20 randomly
selected participants to assess the acceptability, utility
and practicality of intervention components, and useful-
ness of proposed study outcome measures. Interviews
will be conducted using established methods for qualita-
tive process evaluation of trials as developed by Donovan
et al.47 We will use a topic guide to ensure consistency
across participants, but with a ﬂexible format to allow
participants to generate naturalistic data related to their
experience and on what they consider as important
and/or successful in terms of treatment outcomes. For
all SPIN interventions, feasibility study results will be
used to reﬁne the methodology and analysis plans for
the full-scale RCTs.
Full-scale RCTs
In traditional RCTs, the effectiveness of an intervention
may be assessed using per-protocol analysis, which
includes only those patients who successfully completed
the treatment originally allocated, or an intention-to-
treat analysis (ITT), which compares patients in the
groups to which they were originally allocated after ran-
domisation, irrespective of whether or not the patient
received or completed the allocated treatment. ITT is
widely recommended as the preferred analysis, since it
addresses the effectiveness of the intervention for all
patients who agree to attempt the treatment, rather than
only for patients who successfully complete it, as with
per-protocol analysis. The primary analysis for SPIN
trials will be ITT, comparing the outcomes of randomly
selected patients who are offered the intervention, to eli-
gible patients who were not offered the intervention.
In the cmRCT design, however, randomisation occurs
prior to offer of intervention, and some number of eli-
gible patients who are randomly selected to be offered
an intervention will not accept the offer. In addition to
ITT analysis, it is of interest to assess the effect of an
intervention among patients who accept the offer.
Ideally, we would compare outcomes for patients who
accept the offer of the intervention to patients who are
not offered the intervention, but would have accepted if
they had received an offer. This is because patients who
agree to attempt an intervention may be different in
important ways from patients who decline the offer of
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an intervention. Because we cannot actually know which
patients who are not offered the intervention would
have accepted if offered, we will use Complier Average
Causal Effect (CACE) analysis48 49 to make this compari-
son, as a secondary analysis for SPIN trials. CACE
assumes that the proportion of patients in the non-offer
group who would have refused the offer is the same as
for the group who were offered the intervention.
Furthermore, CACE assumes that outcomes are the
same among patients who refuse the intervention and
patients who would have refused the intervention, if
offered. On this basis, an intervention effect can be esti-
mated that compares patients in the offer group who
accepted the intervention offer to patients in the non-
offer group who would have accepted the intervention if
offered (see ﬁgure 2).
All SPIN full-scale trials will be registered50 and will be
conducted and reported in accordance with standards
articulated in the Consolidated Standards of Reporting
Trials (CONSORT) Extension for Non-pharmacological
Trials.51 52 A study protocol for each full-scale trial will
be published, describing the study design and content
of the SPIN intervention.
ETHICS AND DISSEMINATION
The study will be conducted in compliance with the
principles of the Declaration of Helsinki (2008) and
other major ethical guidelines of participating sites,
including Canada’s Tri-Council Policy Statement (2010).
In the cmRCT design, individuals consent to partici-
pate in a cohort for ongoing data collection and to allow
their data to be used for comparison purposes with
patients from the cohort who may be offered to partici-
pate in trials that are conducted within the SPIN
Cohort. At the time of recruitment, written informed
consent will be obtained. The local recruiting SPIN
physician, or supervised nurse coordinator, will explain
the nature and purpose of the Cohort and provide the
participants with a copy of the consent and information
sheet. Recruiting SPIN physicians will provide a descrip-
tion of SPIN and explain that agreeing to participate in
the SPIN Cohort will involve (1) giving the physician or
supervised nurse coordinator permission to complete
the SPIN baseline Medical Data form, using information
from the patient’s medical record; (2) being contacted
by email with instructions on how to complete SPIN
patient measures via the internet at the time of enrol-
ment and periodically going forward (every 3 months);
(3) providing permission for their data to be used to
select them for participation in trials or for comparison
purposes for SPIN intervention trials that may be con-
ducted while they are participating in the SPIN Cohort
and (4) giving permission for SPIN investigators to
contact them with an invitation to participate in SPIN
interventions once developed. Patients will be informed
that participation in the SPIN Cohort will not affect
their usual care in any way. They will also be informed
that only patients who are randomly selected to be
offered an intervention will be contacted about the
intervention. Finally, it is explained that patients’
Figure 2 Outline of complier average causal effect analysis in the cohort multiple randomised controlled trial design.
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current consent is only for participation in the SPIN
Cohort, and that separate consent will be sought for par-
ticipation in a particular SPIN intervention.
Data management and security
All data are entered into a centralised secure electronic
data management system designed, managed and located
at the Data Management Unit of the Centre for Clinical
Epidemiology, Lady Davis Institute for Medical Research, Jewish
General Hospital, Montreal Quebec, Canada. To protect the
participants’ privacy, before the recruiting SPIN physician
at each centre enters the medical data, a unique patient
identiﬁcation number will automatically be assigned to
each participant. Only de-identiﬁed data will be recorded
in the database, with linking data available only to the
SPIN Director. Only personnel authorised by the SPIN
Director will be allowed to retrieve, enter or change data
from the central database, and the database will be
audited for any changes that are made. All data will be
kept for 10 years after completing the cohort study for
ethical and scientiﬁc reasons.
Study management
SPIN was awarded a 5-year Emerging Team Grant for Rare
Diseases from the Canadian Institutes of Health Research
to fund the SPIN Cohort (Funding Reference Number
TR3–119192; Principal Investigator, Brett D. Thombs;
2012–2017). In addition to this funding, SPIN has received
institutional contributions from the Lady Davis Institute
for Medical Research of the Jewish General Hospital,
Montreal, Canada, for database development and from
McGill University, Montreal, Canada for student training.
Previously, SPIN received funds from the Scleroderma
Society of Canada, the Scleroderma Society of Ontario
and Sclérodermie Québec for developmental work.
SPIN’s organisational structure is depicted in ﬁgure 3.
The SPIN Steering Committee is responsible for review of
the SPIN project direction and coherence, including
being informed and advising on Cohort recruitment/
retention and intervention development, feasibility and
full-scale testing of interventions; reviewing and approv-
ing proposals for SPIN publications; being informed of
the ﬁnancial well-being of the project; and helping to
resolve administrative issues.
The SPIN Advisory Board is directed by and largely com-
prised of people living with SSc, supported by expert con-
sultants. The Advisory Board will (1) review the overall
SPIN project and individual SPIN intervention projects
and (2) advise the Steering Committee so that SPIN max-
imally reﬂects the needs of people with SSc and ensures
successful knowledge transfer within the SSc community
and with the broader rare disease community.
Each SPIN project team has a leader, coleader(s), and a
multidisciplinary group of investigators, including at least
two SSc patients. Project teams, supported by the
Steering Committee and SPIN Cores (see below), will
design and test SPIN interventions and work with patient
organisations to facilitate delivery of tested interventions.
SPIN Cores work closely with project teams to support
high-quality investigative work and successful knowledge
transfer. SPIN Cores provide expertise in information
technology for delivering patient-centred healthcare ser-
vices; data management; research methods and biostatis-
tics; measurement of patient-oriented outcomes in SSc;
health economics; knowledge transfer; and bioethics.
The SPIN Data Access and Publication Policy describes
the procedures that will be used to ensure the scientiﬁc
integrity of publications that emerge from SPIN. The
policy ensures that responsibility and credit for SPIN
publications as well as standard authorship requirements
Figure 3 Scleroderma patient-centred intervention network organisational structure.
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(eg, International Committee of Medical Journal
Editors) are met. Proposals to conduct analyses using
SPIN data must be submitted by a SPIN investigator for
review to the Data Access and Publication Committee.
The Committee will ensure that proposed analyses do
not overlap with existing proposals and will review the
proposed methods, in consultation with the SPIN Cores.
It is anticipated that, at the appropriate time, access to
SPIN data will be open to other investigators, consistent
with the policies of the Canadian Institute of Health
Research.53 Prior to providing access to de-identiﬁed
SPIN data to non-SPIN investigators, a Data Sharing
Plan describing the data sharing procedures will be
written and submitted for ethics approval to the
Research Ethics Committee of the Jewish General
Hospital in Montreal, Quebec, Canada.
DISCUSSION
Until recently, the inability to conduct rigorous,
adequately powered trials of psychosocial and rehabilita-
tion interventions in rare diseases has been a barrier to
the development of evidence-based patient-centred care
for people with rare diseases. The novel cmRCT
design33 that will be utilised by SPIN is a promising
approach to move forward research in this area. It will
allow SPIN to both collect important observational data
in a longitudinal cohort and to conduct multiple prag-
matic RCTs in the same cohort.
The use of the cmRCT design in SPIN is highly feas-
ible due to its international multicentre nature. The fea-
tures of the cmRCT design make it a good option for
conducting research in the context of rare chronic dis-
eases, as well as comparing psychosocial and rehabilita-
tion interventions to treatment as usual in pragmatic
trials. There may be a number of circumstances,
however, in which the cmRCT design is less suitable.33
These include, for instance, acute or short-term condi-
tions, double-blinded trials with a placebo arm and treat-
ments for which the uptake by patients may be low. In
addition, the use of relatively easy obtainable patient-
reported outcomes, as in the SPIN Cohort, facilitates
research using the cmRCT design, compared to more
expensive and time-intensive measures such as conduct-
ing laboratory tests, which would not be feasible in the
context of the cmRCT.
The end goal of SPIN is to make psychosocial and
rehabilitation interventions available through patient
organisations. The collaboration of investigators with
patient organisation partners has been crucial in the
establishment of SPIN. Prior to launching SPIN, a series
of projects were conducted in collaboration with patients
from organisations across Canada (eg, Scleroderma
Societies of Canada and Ontario, Sclérodermie Québec,
the Scleroderma Association of British Columbia), the
USA (USA Scleroderma Foundation) and Europe
(Federation of European Scleroderma Associations),
which has helped to better understand important
problems faced by persons living with SSc and to priori-
tise gaps in access to psychosocial and rehabilitation ser-
vices.16 25 54 Each of the proposed SPIN interventions is
grounded in this work, and integrated knowledge trans-
fer will play a major role in developing, adapting and
disseminating interventions to best address the needs of
persons with SSc. Patient advocacy organisations have
committed to working with SPIN on an ongoing basis to
ensure that the interventions developed by SPIN will be
made available to patients once developed and tested.
In summary, SPIN is a unique endeavour to develop
and test psychosocial and rehabilitation care interven-
tions in SSc and to make these interventions accessible
through patient organisations around the world with a
low ongoing cost. Unique features of SPIN, including
the use of the cmRCT design, the development of self-
guided online interventions delivered using a common
platform, and a robust partnership with patient organisa-
tions, may serve as a model to help facilitate research in
this area for other rare diseases as well.
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